| Rang | Wirkstoff | Umsatz in Mrd. USD | Hersteller | Wirkstoffgruppe |
|---|
| 1 | Adalimumab | 10,058 | AbbVie | TNF-Blocker |
| 2 | Fluticason + Salmeterol | 9,064 | GlaxoSmithKline | Corticosteroide + Beta-2-Sympathomimetika |
| 3 | Etanercept | 8,096 | Amgen | TNF-Blocker |
| 4 | Rosuvastatin | 8,025 | AstraZeneca | Statine |
| 5 | Infliximab | 7,805 | Johnson & Johnson, MSD | TNF-Blocker |
| 6 | Esomeprazol | 7,773 | AstraZeneca | Protonenpumpenhemmer |
| 7 | Insulin glargin | 7,773 | Sanofi-Aventis | Insulinanaloga |
| 8 | Aripiprazol | 7,697 | Bristol-Myers Squibb, Otsuka | Atypische Neuroleptika |
| 9 | Duloxetin | 6,373 | Eli Lilly and Company | Serotonin-Noradrenalin-Wiederaufnahmehemmer |
| 10 | Rituximab | 6,154 | Roche | Monoklonale Antikörper: CD20 |
| 11 | Bevacizumab | 5,518 | Roche | Angiogenese-Inhibitoren |
| 12 | Tiotropiumbromid | 5,256 | Boehringer Ingelheim | Anticholinergika |
| 13 | Trastuzumab | 5,064 | Roche | Monoklonale Antikörper: HER2/neu |
| 14 | Pregabalin | 5,060 | Pfizer | Antikonvulsiva |
| 15 | Glatirameracetat | 4,650 | Teva Pharmaceutical Industries | Immunmodulatoren |
| 16 | Ranibizumab | 4,490 | Roche, Novartis | Monoklonale Antikörper: VEGF |
| 17 | Sitagliptin | 4,403 | MSD | Inhibitoren der Dipeptidylpeptidase 4 |
| 18 | Pegfilgrastim | 4,391 | Amgen | Granulozyten-Kolonie stimulierende Faktoren |
| 19 | Imatinib | 4,123 | Novartis | Proteinkinaseinhibitor |
| 20 | Tenofovir | 3,920 | Gilead Sciences | Nukleosidische Reverse-Transkriptase-Inhibitoren |
| 21 | Budesonid | 3,878 | AstraZeneca | Glucocorticoide |
| 22 | Insulin aspart | 3,878 | Novo Nordisk | Insulinanaloga |
| 23 | Tenofovir + Emtricitabin | 3,638 | Gilead Sciences | Nukleosidische Reverse-Transkriptase-Inhibitoren |
| 24 | Valsartan | 3,391 | Novartis | AT1-Antagonisten |
| 25 | Celecoxib | 3,177 | Pfizer | COX-2-Hemmer |
| 26 | Oxycodon | 3,076 | Purdue Pharma | Opioid-Analgetika |
| 27 | Interferon Beta-1A | 3,024 | Biogen Idec | Interferone |
| 28 | Ezetimib | 3,022 | MSD | Cholesterin-Resorptionshemmer |
| 29 | Quetiapin | 2,588 | AstraZeneca | Atypische Neuroleptika |
| 30 | Insulin lispro | 2,584 | Eli Lilly and Company | Insulinanaloga |
| 31 | Enoxaparin-Natrium | 2,569 | Sanofi-Aventis | Antikoagulantien (Heparine) |
| 32 | Atorvastatin | 2,450 | Pfizer | Statine |
| 33 | Pemetrexed | 2,412 | Eli Lilly and Company | Zytostatika |
| 34 | Tadalafil | 2,393 | Eli Lilly and Company | PDE-5-Hemmer |